Semax
Semax is a synthetic heptapeptide derived from the N-terminal of ACTH (4-10).
- Vial Size
- 30mg
- Molecular Weight
- 813.94 g/mol
- Half-life
- Short plasma; extended CNS effects (research models)
- Latest Lot Purity
- 99.69%
Mechanism of Action
Semax is a synthetic heptapeptide derived from the N-terminal of ACTH (4-10). Research focus includes upregulation of BDNF and NGF expression and modulation of cognitive and resilience-related CNS pathways.
Research Context
- Neurotrophic factor (BDNF/NGF) studies
- Cognitive performance research models
- Neuroprotection assays
- Stress-response CNS research
Met-Glu-His-Phe-Pro-Gly-Pro
Lot NX-040 · Verified at 99.69%
Plasma Profile & Protocol
Modelled plasma concentration over time, reconstitution calculator, and a literature-derived research protocol for Semax.
Illustrative Bateman model derived from published half-life and absorption data. For research-context visualisation only.
Solve for syringe units assuming a U-100 insulin syringe. Defaults seeded from the Semax monograph.
U-100 insulin syringe assumed (100 units = 1 mL). For research dosing visualisation only. Verify all dilutions independently.
- Typical Dose
- 200–600 mcg
- Frequency
- 1–3× daily
- Cycle Length
- 2–4 weeks
- Route
- Intranasal or subQ
Note ·Intranasal route common for CNS research endpoints.
Related Compounds
All compounds →
Selank
Anxiolytic neuropeptide studied for stress-response and cognitive models.
For Research Use Only · This monograph summarises publicly available research literature for educational, in-vitro and laboratory research purposes only. Nexora Labs products are not drugs, food, supplements, or cosmetics, and are not intended to diagnose, treat, cure or prevent any condition.